|Day Low/High||18.35 / 18.84|
|52 Wk Low/High||13.02 / 27.85|
This simple option strategy, which I continue to use with small-cap biotechs, is one of the easiest and cheapest risk mitigation approaches an individual can take.
Merger activity is picking up this week in the biotechnology sector and these four promising companies would be good buyout candidates.
The three either have made recent progress toward advancing products in their pipelines or have caught the eye of analysts.
These are just a few of the names I expect to do well to close out 2018.
These are a few of the names I expect to do well to close out 2018.
Market ends flat to close the trading week even as the S&P 500 closes out its best quarter since 2013. A couple of small biotechs made some stealth moves up this week in including Syndax Pharmaceuticals , which broke through resistance. Also, Therav...
I expect deal volume to have a substantial uptick before the end of 2018 rolls around.
These names are moving up or down in a big way ahead of releasing drug-trial results.
Speculative action is keeping sentiment from being more negative.
The biotech sector has seen a big rally, but there are still opportunities.
2:15 pm update Markets are pretty much where they were 90 minutes ago. The S&P has strengthened a bit and overall equities have held up better than I thought given the potential partial government shutdown this weekend. We will see if stocks hold th...